Skip to content

Comparison of the therapeutic efficacy and side effects of tramadol per os (Tradonal Odis® orodispersible tablets) versus an optimised dosis of travenous tramadol for postoperative pain relief in ambulatory surgery.

Comparison of the therapeutic efficacy and side effects of tramadol per os (Tradonal Odis® orodispersible tablets) versus an optimised dosis of travenous tramadol for postoperative pain relief in ambulatory surgery.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-007019-10-BE
Enrollment
200
Registered
2007-12-17
Start date
2008-01-21
Completion date
Unknown
Last updated
2024-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ambulatory surgery

Interventions

Trade Name: Tradonal Odis Product Name: Tradonal Odis Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: TRAMADOL CAS Number: 27203925 Concentration unit: mg milligram(s) Concentration ty

Sponsors

University Hospital Ghent
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ASA I and II female or male patients undergoing wisdom teeth extraction, aged 18-70 years, scheduled for ambulatory surgery requiring postoperative pain medication. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Exclusion criteria included weight less than 70% or more than 130% of ideal body weight, neurological disorder, and recent use of psycho-active medication, including alcohol, patients suffering from chronic pain receiving pre-operative pain medication including NSAID’s, use of chronic anti-emetic medication, use of chronic corticoid therapy. Patients who do not reach a VAS score of 4 or more at PACU arrival will be considered as screening failure and will not be randomized. (They will be replaced by another subject.). In the group receiving tramadol perorally, patients will be excluded if they vomit within 1 hours post administration due to the fact that the tramadol dose might not have been absorbed completely hereby increasing intra-individual variability.

Design outcomes

Primary

MeasureTime frame
Main Objective: The aim of this study is to compare the administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages versus tramadol IV given in 3 unit dosage of 35 mg during the first 6 hours postoperatively and to investigate the time course and accuracy of pain relief versus the onset and duration of side effects. ;Secondary Objective: ;Primary end point(s): Pain relief Duration of side effects

Countries

Belgium

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026